Literature DB >> 26924447

Effects of rapamycin and curcumin treatment on the development of epilepsy after electrically induced status epilepticus in rats.

Cato M Drion1, Lars E Borm1, Lieneke Kooijman1, Eleonora Aronica2,3, Wytse J Wadman1, Aloysius F Hartog4, Erwin A van Vliet2, Jan A Gorter1.   

Abstract

OBJECTIVE: Inhibition of the mammalian target of rapamycin (mTOR) pathway has been suggested as a possible antiepileptogenic strategy in temporal lobe epilepsy (TLE). Here we aim to elucidate whether mTOR inhibition has antiepileptogenic and/or antiseizure effects using different treatment strategies in the electrogenic post-status epilepticus (SE) rat model.
METHODS: Effects of mTOR inhibitor rapamycin were tested using the following three treatment protocols: (1) "stop-treatment"-post-SE treatment (6 mg/kg/day) was discontinued after 3 weeks; rats were monitored for 5 more weeks thereafter, (2) "pretreatment"-rapamycin (3 mg/kg/day) was applied during 3 days preceding SE; and (3) "chronic phase-treatment"-5 days rapamycin treatment (3 mg/kg/day) in the chronic phase. We also tested curcumin, an alternative mTOR inhibitor with antiinflammatory and antioxidant effects, using chronic phase treatment. Seizures were continuously monitored using video-electroencephalography (EEG) recordings; mossy fiber sprouting, cell death, and inflammation were studied using immunohistochemistry. Blood was withdrawn regularly to assess rapamycin and curcumin levels with high performance liquid chromatography (HPLC).
RESULTS: Stop-treatment led to a strong reduction of seizures during the 3-week treatment and a gradual reappearance of seizures during the following 5 weeks. Three days pretreatment did not prevent seizure development, whereas 5-day rapamycin treatment in the chronic phase reduced seizure frequency. Washout of rapamycin was slow and associated with a gradual reappearance of seizures. Rapamycin treatment (both 3 and 6 mg/kg) led to body growth reduction. Curcumin treatment did not reduce seizure frequency or lead to a decrease in body weight. SIGNIFICANCE: The present study indicates that rapamycin cannot prevent epilepsy in the electrical stimulation post-SE rat model but has seizure-suppressing properties as long as rapamycin blood levels are sufficiently high. Oral curcumin treatment had no effect on chronic seizures, possibly because it did not reach the brain at adequate levels. Wiley Periodicals, Inc.
© 2016 International League Against Epilepsy.

Entities:  

Keywords:  Chronic seizures; EEG; Epileptogenesis; Temporal lobe epilepsy

Mesh:

Substances:

Year:  2016        PMID: 26924447     DOI: 10.1111/epi.13345

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  17 in total

1.  ER-stress mobilization of death-associated protein kinase-1-dependent xenophagy counteracts mitochondria stress-induced epithelial barrier dysfunction.

Authors:  Fernando Lopes; Åsa V Keita; Alpana Saxena; Jose Luis Reyes; Nicole L Mancini; Ala Al Rajabi; Arthur Wang; Cristiane H Baggio; Michael Dicay; Rob van Dalen; Younghee Ahn; Matheus B H Carneiro; Nathan C Peters; Jong M Rho; Wallace K MacNaughton; Stephen E Girardin; Humberto Jijon; Dana J Philpott; Johan D Söderholm; Derek M McKay
Journal:  J Biol Chem       Date:  2018-01-09       Impact factor: 5.157

Review 2.  Chronobiology of limbic seizures: Potential mechanisms and prospects of chronotherapy for mesial temporal lobe epilepsy.

Authors:  Daniel Leite Góes Gitai; Tiago Gomes de Andrade; Ygor Daniel Ramos Dos Santos; Sahithi Attaluri; Ashok K Shetty
Journal:  Neurosci Biobehav Rev       Date:  2019-01-07       Impact factor: 8.989

3.  Akt Inhibitor Perifosine Prevents Epileptogenesis in a Rat Model of Temporal Lobe Epilepsy.

Authors:  Feng Zhu; Jiejing Kai; Linglin Chen; Meiling Wu; Jingyin Dong; Qingmei Wang; Ling-Hui Zeng
Journal:  Neurosci Bull       Date:  2017-08-07       Impact factor: 5.203

4.  Metformin ameliorates the status epilepticus- induced hippocampal pathology through possible mTOR modulation.

Authors:  Sree Lalitha Bojja; Bikash Medhi; Shashi Anand; Alka Bhatia; Rupa Joshi; Ranjana W Minz
Journal:  Inflammopharmacology       Date:  2021-01-01       Impact factor: 4.473

Review 5.  Curcumin: A Review of Its Effects on Epilepsy.

Authors:  Fatemeh Forouzanfar; Muhammed Majeed; Tannaz Jamialahmadi; Amirhosein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  Neuroinflammatory targets and treatments for epilepsy validated in experimental models.

Authors:  Eleonora Aronica; Sebastian Bauer; Yuri Bozzi; Matteo Caleo; Raymond Dingledine; Jan A Gorter; David C Henshall; Daniela Kaufer; Sookyong Koh; Wolfgang Löscher; Jean-Pierre Louboutin; Michele Mishto; Braxton A Norwood; Eleonora Palma; Michael O Poulter; Gaetano Terrone; Annamaria Vezzani; Rafal M Kaminski
Journal:  Epilepsia       Date:  2017-07       Impact factor: 5.864

7.  Development of an antiepileptogenesis drug screening platform: Effects of everolimus and phenobarbital.

Authors:  Melissa Barker-Haliski; Kevin Knox; Dannielle Zierath; Zachery Koneval; Cameron Metcalf; Karen S Wilcox; H Steve White
Journal:  Epilepsia       Date:  2021-06-02       Impact factor: 6.740

Review 8.  Therapeutic role of targeting mTOR signaling and neuroinflammation in epilepsy.

Authors:  Samantha L Hodges; Joaquin N Lugo
Journal:  Epilepsy Res       Date:  2020-01-30       Impact factor: 2.991

9.  Liposomal Encapsulated Curcumin Effectively Attenuates Neuroinflammatory and Reactive Astrogliosis Reactions in Glia Cells and Organotypic Brain Slices.

Authors:  Christina Schmitt; Anna Lechanteur; François Cossais; Coralie Bellefroid; Philipp Arnold; Ralph Lucius; Janka Held-Feindt; Geraldine Piel; Kirsten Hattermann
Journal:  Int J Nanomedicine       Date:  2020-05-25

Review 10.  Commonalities in epileptogenic processes from different acute brain insults: Do they translate?

Authors:  Pavel Klein; Raymond Dingledine; Eleonora Aronica; Christophe Bernard; Ingmar Blümcke; Detlev Boison; Martin J Brodie; Amy R Brooks-Kayal; Jerome Engel; Patrick A Forcelli; Lawrence J Hirsch; Rafal M Kaminski; Henrik Klitgaard; Katja Kobow; Daniel H Lowenstein; Phillip L Pearl; Asla Pitkänen; Noora Puhakka; Michael A Rogawski; Dieter Schmidt; Matti Sillanpää; Robert S Sloviter; Christian Steinhäuser; Annamaria Vezzani; Matthew C Walker; Wolfgang Löscher
Journal:  Epilepsia       Date:  2017-12-15       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.